Inventor · disambiguated record
Johnny Y. Nagasawa
Also filed as: NAGASAWA JOHNNY Y · NAGASAWA JOHNNY YASUO
27 granted patents·19 pending applications·425 citations·filing 2004–2022
97Inventor score
Files withMETACRINE INC15CYLENE PHARMACEUTICALS INC4GENENTECH INC4SERAGON PHARMACEUTICALS INC4FL2022 001 INC3
Top patents by PatentIndex Score
46 records- 0197US8455534B2Estrogen receptor modulators and uses thereofSMITH NICHOLAS D·Filed 2012·Granted Jun 4, 2013·66 cites·18 claims
- 0297US8299112B2Estrogen receptor modulators and uses thereofSMITH NICHOLAS D·Filed 2011·Granted Oct 30, 2012·72 cites·12 claims
- 0396US9078871B2Estrogen receptor modulators and uses thereofSERAGON PHARMACEUTICALS INC·Filed 2013·Granted Jul 14, 2015·50 cites·22 claims
- 0496US8703810B2Estrogen receptor modulators and uses thereofKAHRAMAN MEHMET·Filed 2011·Granted Apr 22, 2014·65 cites·21 claims
- 0595US7928100B2Quinolone analogs and methods related theretoCYLENE PHARMACEUTICALS INC·Filed 2008·Granted Apr 19, 2011·23 cites·2 claims
- 0692US9845291B2Estrogen receptor modulators and uses thereofGENENTECH INC·Filed 2015·Granted Dec 19, 2017·15 cites·14 claims
- 0791US10626081B2Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2016·Granted Apr 21, 2020·4 cites·18 claims
- 0891US9193714B2Fluorinated estrogen receptor modulators and uses thereofSERAGON PHARMACEUTICALS INC·Filed 2012·Granted Nov 24, 2015·18 cites·14 claims
- 0991US7816406B2Quinolone analogsCYLENE PHARMACEUTICALS INC·Filed 2005·Granted Oct 19, 2010·11 cites·17 claims
- 1091US7655649B2Inhibitors of Akt activityMERCK SHARP & DOHME·Filed 2005·Granted Feb 2, 2010·20 cites·8 claims
- 1188US9187460B2Estrogen receptor modulators and uses thereofSERAGON PHARMACEUTICALS INC·Filed 2012·Granted Nov 17, 2015·11 cites·17 claims
- 1287US10927082B2Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2020·Granted Feb 23, 2021·2 cites·2 claims
- 1387US7816524B2Methods of preparing quinolone analogsCYLENE PHARMACEUTICALS INC·Filed 2006·Granted Oct 19, 2010·10 cites·22 claims
- 1486US10961198B2Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2018·Granted Mar 30, 2021·2 cites·4 claims
- 1586US8168651B2Protein kinase modulatorsCHUA PETER C·Filed 2009·Granted May 1, 2012·11 cites·11 claims
- 1685US8003643B2Inhibitors of Akt activityMERCK SHARP & DOHME·Filed 2009·Granted Aug 23, 2011·7 cites·8 claims
- 1784US8853234B2Quinolone analogs and methods related theretoNAGASAWA JOHNNY YASUO·Filed 2011·Granted Oct 7, 2014·13 cites·18 claims
- 1883US10703712B2Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2016·Granted Jul 7, 2020·2 cites·16 claims
- 1983US9399646B2Estrogen receptor modulators and uses thereofSMITH NICHOLAS D·Filed 2011·Granted Jul 26, 2016·6 cites·15 claims
- 2082US11236071B1Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2018·Granted Feb 1, 2022·2 cites·18 claims
- 2179US7834180B2Methods of preparing quinolone analogsCYLENE PHARMACEUTICALS INC·Filed 2008·Granted Nov 16, 2010·3 cites·22 claims
- 2278US9499538B2Estrogen receptor modulators and uses thereofSERAGON PHARMACEUTICALS INC·Filed 2013·Granted Nov 22, 2016·4 cites·13 claims
- 2377US10053451B2Heterocyclic estrogen receptor modulators and uses thereofGENENTECH INC·Filed 2016·Granted Aug 21, 2018·2 cites·10 claims
- 2471US2022081390A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2021·Application pending·0 cites
- 2569US7235662B2Modulators of the glucocorticoid receptor and methodBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Jun 26, 2007·6 cites·18 claims
- 2668US2021300875A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2021·Application pending·0 cites
- 2766US11214538B2Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2020·Granted Jan 4, 2022·0 cites·18 claims
- 2866US2022089575A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2021·Application pending·0 cites
- 2961US2022002309A1Ssao inhibitors and uses thereofMETACRINE INC·Filed 2019·Application pending·0 cites
- 3061US2024368127A1Hsd17b13 inhibitors and uses thereofFL2022 001 INC·Filed 2022·Application pending·0 cites
- 3160US9868704B2Estrogen receptor modulators and uses thereofGENENTECH INC·Filed 2016·Granted Jan 16, 2018·0 cites·18 claims
- 3260US8124649B2Oxindole compoundsHADDACH MUSTAPHA·Filed 2009·Granted Feb 28, 2012·0 cites·21 claims
- 3359US2020181104A1Ssao inhibitors and uses thereofMETACRINE INC·Filed 2020·Application pending·0 cites
- 3457US2024034736A1Hsd17b13 inhibitors and uses thereofFL2022 001 INC·Filed 2021·Application pending·0 cites
- 3557US2024083861A1Hsd17b13 inhibitors and uses thereofFL2022 001 INC·Filed 2021·Application pending·0 cites
- 3655US2011166123A1Novel compositions and methods of useAARDEA BIOSCIENCES INC·Filed 2009·Application pending·0 cites
- 3749US2011269741A1Novel compositions and methods of useARDEA BIOSCIENCES INC·Filed 2011·Application pending·0 cites
- 3849US2011065687A1Hydrazide compounds and uses thereofSCHWAEBE MICHAEL·Filed 2008·Application pending·0 cites
- 3946US2022056019A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2019·Application pending·0 cites
- 4046US2012190669A1Oxindole compoundsHADDACH MUSTAPHA·Filed 2012·Application pending·0 cites
- 4146US2012208792A1Protein kinase modulatorsCHUA PETER C·Filed 2011·Application pending·0 cites
- 4243US2010305136A1Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamideNAGASAWA JOHNNY YASUO·Filed 2007·Application pending·0 cites
- 4343US2020131132A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2018·Application pending·0 cites
- 4441US2020131129A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2018·Application pending·0 cites
- 4540US2020131142A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2018·Application pending·0 cites
- 4637US2016175284A1Estrogen receptor modulators and uses thereofGENENTECH INC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →